Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07118085) titled 'A Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMC-003 for Injection in Healthy Postmenopausal Women' on Aug. 5.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).

Primary Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Condition: Healthy Postmenopausal Women

Intervention: Drug: experimental Arm IMC-003

Recruitment Status: Not...